Thunder Biotech, Inc.
Genetically engineered macrophages for CAR immunotherapy targeting solid tumors
- Sector
- Biotech
- Headquarters
- PROVO, UT
- Founded
- 2016
- Latest Form D
- $100K, Feb 2024
- Total capital
- $24.5M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $24.5M
- 7 Form D · last Feb 2024
- 32 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 8 pending · first 2019
- Rank in peer group#339 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 7th filing$100K
- Private capital raisedForm D · SEC · 6th filing$1M
- Private capital raisedForm D · SEC · 5th filing$4M
- Private capital raisedForm D · SEC · 4th filing$10M
- Private capital raisedForm D · SEC · 3rd filing$8.3M
- Private capital raisedForm D · SEC · 2nd filing$325K
- Private capital raisedForm D · SEC · 1st filing$770K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#339 · top 23%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Kim L. O'NeillResearcherExecutive Officer, DirectorLinked by 1 patent
- Barry MowerDirectorNamed in SEC Form D filings
- D. Brent IsraelsenExecutive Officer, DirectorNamed in SEC Form D filings
- D. Todd SchulthessExecutive Officer, Director, PromoterNamed in SEC Form D filings
- James A. BurgessExecutive OfficerNamed in SEC Form D filings
- J. Anthony AntonelliDirectorNamed in SEC Form D filings
Show all 13 people
- Jeff HoneExecutive Officer, DirectorNamed in SEC Form D filings
- Jeffrey NelsonDirectorNamed in SEC Form D filings
- Kent MisenerDirectorNamed in SEC Form D filings
- Morris L. LintonExecutive OfficerNamed in SEC Form D filings
- Robert P.K. MooneyExecutive Officer, DirectorNamed in SEC Form D filings
- Scott PetersonDirectorNamed in SEC Form D filings
- Steven A. TannerDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 11- PendingMethod of Targeting Cells and Associated CompositionsUSPTOApplication 18573239
- PendingTransgenic Macrophages, Chimeric Antigen Receptors, and Associated MethodsUSPTOApplication 18731958
- GrantedTransgenic Macrophages, Chimeric Antigen Receptors, and Associated MethodsUSPTOUS 12,024,719
Show all 11 patent records
- Method of Targeting Cells and Associated CompositionsMar 13, 2025 · Application 18573239Pending
- Transgenic Macrophages, Chimeric Antigen Receptors, and Associated MethodsMar 6, 2025 · Application 18731958Pending
- Transgenic Macrophages, Chimeric Antigen Receptors, and Associated MethodsJul 2, 2024 · US 12,024,719Granted
- Modified Macrophages And Macrophage Precursors And Associated MethodsFeb 25, 2021 · Application 16959505Pending
- Transgenic Macrophages, Chimeric Antigen Receptors, And Associated MethodsJan 12, 2021 · US 10,889,803Granted
- Transgenic Macrophages, Chimeric Antigen Receptors, And Associated MethodsSep 17, 2019 · US 10,415,017Granted
- Method Of Targeting Cells And Associated CompositionsApplication 63214544Pending
- Modified Macrophages And Macrophage Precursors And Associated MethodsApplication 62614183Pending
- Transgenic Macrophages, Chimeric Antigen Receptors, And Associated MethodsApplication PCTUS2017033039Pending
- Modified Macrophages And Macrophage Precursors And Associated MethodsApplication PCTUS2018065543Pending
- Method Of Targeting Cells And Associated CompositionsApplication PCTUS2022034940Pending
Related companies, and why
- Inductive Bio, Inc.Similar federal contract value in Biotech · null in contracts
- GB SCIENCES INCSimilar federal contract value in Biotech · null in contracts
- Aldeyra TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Trait Biosciences Inc.Similar federal contract value in Biotech · null in contracts
- Core Quantum Technologies, Inc.Similar federal contract value in Biotech · null in contracts
- GENVAX TECHNOLOGIES INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .